Christopher R. Fenimore - Dec 8, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Signature
/s/**Christopher R. Fenimore
Stock symbol
REGN
Transactions as of
Dec 8, 2023
Transactions value $
-$1,696,479
Form type
4
Date filed
12/12/2023, 04:01 PM
Previous filing
Aug 25, 2023
Next filing
Dec 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability -$400K -474 -2.26% $843.79 20.5K Dec 8, 2023 Direct
transaction REGN Common Stock Award $0 +2.37K +11.58% $0.00 22.8K Dec 8, 2023 Direct F1
transaction REGN Common Stock Tax liability -$1.08M -1.28K -5.59% $844.09 21.6K Dec 11, 2023 Direct
transaction REGN Common Stock Tax liability -$219K -260 -1.21% $844.09 21.3K Dec 11, 2023 Direct
holding REGN Common Stock 1.47K Dec 8, 2023 2021 GRAT
holding REGN Common Stock 4.27K Dec 8, 2023 2022 GRAT
holding REGN Common Stock 1.5K Dec 8, 2023 By 401(k) Plan
holding REGN Common Stock 1.9K Dec 8, 2023 By Trust F2
holding REGN Common Stock 461 Dec 8, 2023 by Trust for Daugh
holding REGN Common Stock 460 Dec 8, 2023 by Trust for Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +8.5K $0.00 8.5K Dec 8, 2023 Common Stock 8.5K $843.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027.
F2 These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F3 The stock option award vests in four equal annual installments, commencing one year after the date of grant.